EUVIMEDEUVIMED entdecken
Vergleichsstudie

Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations

Georges Gebrael, Luis Meza, Xiaochen Li, Zeynep Zengin, Nicolas Sayegh, Hedyeh Ebrahimi, Nishita Tripathi, Daniela Castro, Benjamin Mercier, Regina Barragan-Carrillo, Haoran Li, Alexander Chehrazi-Raffle und 5 weitere

European Urology Focus · 2024

DOI: 10.1016/j.euf.2024.03.006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Urology Focus, 2024. Verfasst von Georges Gebrael und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: The impact of time of metastasis onset with respect toprimary renal cell carcinoma (RCC) diagnosis on survival outcomes is not well characterized in the era of immune checkpoint inhibitor (ICI)-based combinations. Herein, we assessed differences in clinical outcomes between synchronous and metachronous metastatic RCC (mRCC). METHODS: Data for patients with mRCC treated with first-line ICI-based combination therapies between 2014 and 2023 were retrospectively collected. Patients were categorized as having synchronous metastasis if present within 3 mo of RCC diagnosis; metachronous metastasis was defined as metastasis >3 mo after primary diagnosis. Time to treatment failure (TTF), overall survival (OS), and the disease control rate (DCR) were assessed. KEY FINDINGS AND LIMITATIONS: Our analysis included 223 eligible patients (126 synchronous and 97 metachronous). Median TTF did not significantly differ between the synchronous and metachronous groups (9 vs 19.8 mo; p = 0.063). Median OS was significantly shorter in the synchronous group (28.0 vs 50.9 mo; p = 0.001). Similarly, patients with synchronous metastasis had lower DCR compared to metachronous metastasis (58.7% vs. 78.4%; p = 0.002). On multivariable analyses, synchronous metastasis remained independently associated with worse OS and DCR. CONCLUSIONS AND CLINICAL IMPLICATIONS: In this hypothesis-generating study, patients with mRCC with synchronous metastasis who were treated with first-line ICI-based combinations have a poorer OS and worse DCR than those with metachronous mRCC. If these results are externally validated, time to metastasis could be included in prognostic models for mRCC. PATIENT SUMMARY: Our study demonstrates that patients treated with current first-line immunotherapies, who present with metastasis at the initial diagnosis of kidney cancer have worse overall survival compared to those who develop metastasis later. These results can help physicians and patients understand life expectancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeSurvival RateNeoplasms, Second PrimaryNeoplasms, Multiple PrimaryNeoplasm Metastasis

Stichwörter der Autor:innen

Immune checkpoint inhibitorsMetachronousMetastatic renal cell carcinomaSurvival outcomesSynchronous

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Department of Internal Medicine, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA.
  • Department of Internal Medicine, Division of Medical Oncology, University of Kansas Cancer Center, Westwood, KS, USA.
  • Department of Internal Medicine, Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: benjamin.maughan@hci.utah.edu.

Zitieren

APA

Gebrael, G., Meza, L., Li, X., Zengin, Z., Sayegh, N., Ebrahimi, H., Tripathi, N., Castro, D., Mercier, B., Barragan-Carrillo, R., Li, H., Chehrazi-Raffle, A., Swami, U., Tripathi, A., Agarwal, N., Maughan, B. L., & Pal, S. K. (2024). Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations. European Urology Focus. https://doi.org/10.1016/j.euf.2024.03.006

Vancouver

Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, et al. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations. European Urology Focus. 2024. doi:10.1016/j.euf.2024.03.006

BibTeX
@article{Gebrael2024,
  author = {Gebrael, Georges and Meza, Luis and Li, Xiaochen and Zengin, Zeynep and Sayegh, Nicolas and Ebrahimi, Hedyeh and Tripathi, Nishita and Castro, Daniela and Mercier, Benjamin and Barragan-Carrillo, Regina and Li, Haoran and Chehrazi-Raffle, Alexander and Swami, Umang and Tripathi, Abhishek and Agarwal, Neeraj and Maughan, Benjamin L and Pal, Sumanta K},
  title = {Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations},
  journal = {European Urology Focus},
  year = {2024},
  doi = {10.1016/j.euf.2024.03.006}
}
Kostenlos starten →